GlaxoSmithKline and Theravance have announced top-line data from pivotal phase III studies of Relovair.

TOKYO and SOUTH SAN FRANCISCO, CA-- - Astellas Pharma Inc. and Theravance, Inc. today announced that Astellas has exercised its right to terminate the global License, Development and Commercialization ...

BOSTON (MarketWatch) -- Shares of Theravance Inc. made a modest rebound in midday trading Wednesday, two days after they were battered by mixed Phase III study results for its respiratory drug candidate Relovair. Theravance shares were up 7% at $17.76. Theravance is developing the product with GlaxoSmithKline PLC as a successor to Glaxo's blockbuster asthma treatment Advair. Glaxo shares were up ...

LONDON and SOUTH SAN FRANCISCO, CA-- - GlaxoSmithKline and Theravance, Inc. today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* ...

GlaxoSmithKline ( GSK ) and Theravance, Inc. ( THRX ) recently announced top-line data from pivotal phase III studies conducted with pipeline candidate, Relovair,

Theravance and partner Glaxo will seek Relovair approvals but data raise safety and efficacy questions. Click to view a price quote on THRX . Click to research the Drugs industry.

Theravance Inc. (THRX) , a maker of treatments for respiratory disorders and bacterial infections, fell the most in more than three years after an experimental medicine it shares with GlaxoSmithKline Plc (GSK) failed to beat an existing drug in a study.

Theravance Inc. (THRX) and GlaxoSmithKline (GSK) announced the initial outcomes from Phase III studies of once-daily Relovair Monday morning.

Is this meaningful? Or just another movement?

SOUTH SAN FRANCISCO, CA-- - Theravance, Inc. announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on ...